FY2026 EPS Estimates for MeiraGTx Increased by HC Wainwright

Key Points

• HC Wainwright raised its FY2026 EPS estimate for MeiraGTx to $0.36 from a prior forecast of a $1.89 loss, while maintaining a “Buy” rating and $20 price target.
• MeiraGTx reported quarterly EPS of $1.71, far above the consensus estimate of a $0.46 loss, alongside revenue of $321.43 million versus estimates of roughly $0.70 million.
• Analyst sentiment remains broadly positive: the stock has a consensus “Buy” rating and an average price target of $26.17, though recent insider stock sales and equity financing for the bota-vec acquisition could create dilution concerns.

MeiraGTx Holdings PLC (NASDAQ:MGTX - Free Report) - Equities research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for shares of MeiraGTx in a report issued on Thursday, August 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of $0.36 for the year, up from their prior forecast of ($1.89). HC Wainwright currently has a "Buy" rating and a $20.00 target price on the stock. The consensus estimate for MeiraGTx's current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for MeiraGTx's Q4 2026 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.48) EPS, Q4 2027 earnings at ($0.08) EPS and FY2027 earnings at ($1.45) EPS.

MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.46) by $2.17. The company had revenue of $321.43 million for the quarter, compared to analyst estimates of $0.70 million. MeiraGTx had a return on equity of 283.85% and a net margin of 19.87%.

A number of other analysts have also recently commented on the stock. Royal Bank Of Canada boosted their target price on shares of MeiraGTx from $26.00 to $27.00 and gave the company an "outperform" rating in a report on Friday. Wall Street Zen upgraded shares of MeiraGTx from a "hold" rating to a "buy" rating in a research note on Saturday. Piper Sandler lifted their price target on shares of MeiraGTx from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Wednesday, April 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of MeiraGTx in a research note on Friday, July 17th. Finally, Zacks Research upgraded shares of MeiraGTx from a "hold" rating to a "strong-buy" rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $26.17.

MeiraGTx Price Performance

MGTX opened at $13.52 on Monday. The company has a current ratio of 3.76, a quick ratio of 3.76 and a debt-to-equity ratio of 0.46. The company has a market cap of $1.30 billion, a price-to-earnings ratio of 19.04 and a beta of 1.23. The stock has a fifty day simple moving average of $12.09 and a two-hundred day simple moving average of $9.83. MeiraGTx has a 12-month low of $6.62 and a 12-month high of $15.35.

Insider Activity

In other MeiraGTx news, insider Stuart Naylor sold 27,659 shares of MeiraGTx stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $14.80, for a total value of $409,353.20. Following the completion of the sale, the insider owned 640,846 shares of the company's stock, valued at approximately $9,484,520.80. The trade was a 4.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Richard Giroux sold 56,000 shares of the business's stock in a transaction on Tuesday, July 21st. The shares were sold at an average price of $12.51, for a total transaction of $700,560.00. Following the sale, the chief financial officer owned 908,530 shares of the company's stock, valued at approximately $11,365,710.30. This represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 145,659 shares of company stock valued at $1,678,453 over the last three months. Insiders own 7.40% of the company's stock.

Institutional Trading of MeiraGTx

Several large investors have recently modified their holdings of MGTX. AQR Capital Management LLC purchased a new stake in MeiraGTx during the first quarter valued at $557,000. Rhumbline Advisers lifted its holdings in MeiraGTx by 9.4% in the second quarter. Rhumbline Advisers now owns 63,715 shares of the company's stock valued at $415,000 after acquiring an additional 5,488 shares during the period. Brown Advisory Inc. purchased a new position in MeiraGTx in the second quarter worth about $326,000. Qube Research & Technologies Ltd purchased a new position in MeiraGTx in the second quarter worth about $530,000. Finally, Quantinno Capital Management LP bought a new stake in shares of MeiraGTx during the 2nd quarter valued at about $319,000. Institutional investors own 67.48% of the company's stock.

MeiraGTx News Summary

Here are the key news stories impacting MeiraGTx this week:

• Positive Sentiment: RBC raised its price target to $27 from $26 and maintained an “outperform” rating. The new target implies substantial potential upside from the reported $13.52 trading level, providing a bullish signal from a major analyst. Benzinga
• Positive Sentiment: MeiraGTx reported second-quarter EPS of $1.71, significantly exceeding consensus expectations for a loss. Revenue reached $321.43 million versus an analyst estimate of approximately $0.70 million, and the company swung to a quarterly profit from a year-earlier loss. The magnitude of the beat is likely a key driver of the stock’s advance, though investors may assess how much of the results reflects recurring operations versus nonrecurring items. MeiraGTx Swings to Q2 Profit, Revenue Rises
• Positive Sentiment: The company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year Phase 1 AQUAx data for radiation-induced dry mouth. It also acquired rights to bota-vec for X-linked retinitis pigmentosa and expects global regulatory filings in 2026, with a potential AAV2-hAQP1 BLA filing in mid-2027. MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
• Neutral Sentiment: A comparison of MeiraGTx with Biomea Fusion provides sector context but does not introduce a new company-specific catalyst. Head-To-Head Survey: Biomea Fusion and MeiraGTx
• Negative Sentiment: MeiraGTx funded the bota-vec acquisition with a $100 million equity financing, which may create shareholder dilution. However, the transaction also includes up to $400 million of strategic investment, including as much as $375 million in non-dilutive capital.

About MeiraGTx

MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx's pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies.

The company's lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source